Inherited Predisposition to Acute Myeloid Leukemia

Seminars in Hematology

Volumn 51, Issue 4, 2014, Pages 306-321

  Godley, Lucy A ^a  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR RUNX1; CCAAT ENHANCER BINDING PROTEIN; CEBPA PROTEIN, HUMAN; GATA2 PROTEIN, HUMAN; RUNX1 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ARTICLE; BONE MARROW DEPRESSION; CLINICAL LABORATORY; DISEASE PREDISPOSITION; DYSKERATOSIS CONGENITA; FANCONI ANEMIA; GENE; GENE MUTATION; GENE REARRANGEMENT; GENETIC COUNSELING; HEREDITY; HUMAN; MOLECULAR PATHOLOGY; MONOCYTE; MYELODYSPLASTIC SYNDROME; PHENOTYPE; POINT MUTATION; PROGNOSIS; PROPENSITY SCORE; RUNX1 GENE; TELOMERE; THROMBOCYTE DISORDER; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; TRANSLATIONAL RESEARCH; ACUTE MYELOBLASTIC LEUKEMIA; GENETIC PREDISPOSITION; GENETICS; MUTATION;

CCAAT-ENHANCER-BINDING PROTEINS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; GATA2 TRANSCRIPTION FACTOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION;

EID: 84907998950     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2014.08.001     Document Type: Article

References (116)

1. Nickels E.M., Soodalter J., Churpek J.E., Godley L.A. Recognizing familial myeloid leukemia in adults. Ther Adv Hematol 2013, 4:254-269.
2. West A.H., Godley L.A., Churpek J.E. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Ann N Y Acad Sci 2014, 1310:111-118.
3. Seif A.E. Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis. Cancer Genet 2011, 204:227-244.
4. Churpek J.E., Lorenz R., Nedumgottil S., et al. Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leuk Lymphoma 2013, 54:28-35.
5. Huzen J., Wong L.S., van Veldhuisen D.J., et al. Telomere length loss due to smoking and metabolic traits. J Intern Med 2014, 275:155-163.
6. Savage S.A. Dyskeratosis Congenita 2013, University of Washington, Seattle, Seattle, WA.
7. Fogarty P.F., Yamaguchi H., Wiestner A., et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet 2003, 362:1628-1630.
8. Owen C.J., Toze C.L., Koochin A., et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood 2008, 112:4639-4645.
9. Buijs A., Poddighe P., van Wijk R., et al. A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. Blood 2001, 98:2856-2858.
10. Toya T., Yoshimi A., Morioka T., et al. Development of hairy cell leukemia in familial platelet disorder with predisposition to acute myeloid leukemia. Platelets 2014, 25:300-302.
11. Arepally G., Rebbeck T.R., Song W., et al. Evidence for genetic homogeneity in a familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML). Blood 1998, 92:2600-2602.
12. Song W.J., Sullivan M.G., Legare R.D., et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999, 23:166-175.
13. Michaud J., Wu F., Osato M., et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood 2002, 99:1364-1372.
14. Béri-Dexheimer M., Latger-Cannard V., Philippe C., et al. Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions. Eur J Hum Genet 2008, 16:1014-1018.
15. Kirito K., Sakoe K., Shinoda D., et al. A novel RUNX1 mutation in familial platelet disorder with propensity to develop myeloid malignancies. Haematologica 2008, 93:155-156.
16. Preudhomme C., Renneville A., Bourdon V., et al. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood 2009, 113:5583-5587.
17. Churpek J.E., Garcia J.S., Madzo J., et al. Identification and molecular characterization of a novel 3' mutation in RUNX1 in a family with familial platelet disorder. Leuk Lymphoma 2010, 51:1931-1935.
18. van der Crabben S., van Binsbergen E., Ausems M., et al. Constitutional RUNX1 deletion presenting as non-syndromic thrombocytopenia with myelodysplasia: 21q22 ITSN1 as a candidate gene in mental retardation. Leuk Res 2010, 34. e8-12.
19. Jongmans M.C., Kuiper R.P., Carmichael C.L., et al. Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome. Leukemia 2010, 24:242-246.
20. Shinawi M., Erez A., Shardy D.L., et al. Syndromic thrombocytopenia and predisposition to acute myelogenous leukemia caused by constitutional microdeletions on chromosome 21q. Blood 2008, 112:1042-1047.
21. Katzaki E., Morin G., Pollazzon M., et al. Syndromic mental retardation with thrombocytopenia due to 21q22.11q22.12 deletion: report of three patients. Am J Med Gen Part A 2010, 152A:1711-1717.
22. Izumi K., Brooks S.S., Feret H.A., Zackai E.H. 1.9 Mb microdeletion of 21q22.11 within Braddock-Carey contiguous gene deletion syndrome region: dissecting the phenotype. Am J Med Gen Part A 2012, 158A:1535-1541.
23. Melis D., Genesio R., Cappuccio G., et al. Mental retardation, congenital heart malformation, and myelodysplasia in a patient with a complex chromosomal rearrangement involving the critical region 21q22. Am J Med Gen Part A 2011, 155A:1697-1705.
24. Jalagadugula G., Mao G., Kaur G., et al. Platelet protein kinase C-theta deficiency with human RUNX1 mutation: PRKCQ is a transcriptional target of RUNX1. Arteriosclerosis Thrombosis Vasc Biol 2011, 31:921-927.
25. Jalagadugula G., Mao G., Kaur G., et al. Regulation of platelet myosin light chain (MYL9) by RUNX1: implications for thrombocytopenia and platelet dysfunction in RUNX1 haplodeficiency. Blood 2010, 116:6037-6045.
26. Kaur G., Jalagadugula G., Mao G., Rao A.K. RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. Blood 2010, 115:3128-3135.
27. Antony-Debre I., Bluteau D., Itzykson R., et al. MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations. Blood 2012, 120:2719-2722.
28. Bluteau D., Balduini A., Balayn N., et al. Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. J Clin Invest 2014, 124:580-591.
29. Stockley J., Morgan N.V., Bem D., et al. Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects. Blood 2013, 122:4090-4093.
30. Owen C., Barnett M., Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia-a review. Br J Haematol 2008, 140:123-132.
31. Noris P., Perrotta S., Seri M., et al. Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood 2011, 117:6673-6680.
32. Noris P., Favier R., Alessi M.C., et al. ANKRD26-related thrombocytopenia and myeloid malignancies. Blood 2013, 122:1987-1989.
33. Marquez R., Hantel A., Lorenz R., et al. A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies. Leuk Lymphoma 2014 Apr 22, [E-pub ahead of print].
34. Pippucci T., Savoia A., Perrotta S., et al. Mutations in the 5[U+05F3] UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2. Am J Hum Genet 2011, 88:115-120.
35. Al Daama S.A., Housawi Y.H., Dridi W., et al. A missense mutation in ANKRD26 segregates with thrombocytopenia. Blood 2013, 122:461-462.
36. Necchi V., Balduini A., Noris P., et al. Ubiquitin/proteasome-rich particulate cytoplasmic structures (PaCSs) in the platelets and megakaryocytes of ANKRD26-related thrombo-cytopenia. Thrombosis Haemostasis 2013, 109:263-271.
37. Ishida H., Imai K., Honma K., et al. GATA-2 anomaly and clinical phenotype of a sporadic case of lymphedema, dendritic cell, monocyte, B- and NK-cell (DCML) deficiency, and myelodysplasia. Eur J Pediatr 2012, 171:1273-1276.
38. Micol J.B., Abdel-Wahab O. Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations. Haematologica 2014, 99:201-203.
39. Tsai F.Y., Keller G., Kuo F.C., et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 1994, 371:221-226.
40. Rodrigues N.P., Janzen V., Forkert R., et al. Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis. Blood 2005, 106:477-484.
41. Kazenwadel J., Secker G.A., Liu Y.J., et al. Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. Blood 2012, 119:1283-1291.
42. West R.R., Hsu A.P., Holland S.M., et al. Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation. Haematologica 2014, 99:276-281.
43. Bodor C., Renneville A., Smith M., et al. Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival. Haematologica 2012, 97:890-894.
44. Abdel-Wahab O., Adli M., LaFave L.M., et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012, 22:180-193.
45. Scheuermann J.C., de Ayala Alonso A.G., Oktaba K., et al. Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB. Nature 2010, 465:243-247.
46. Abdel-Wahab O., Gao J., Adli M., et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med 2013, 210:2641-2659.
47. Hahn C.N., Chong C.E., Carmichael C.L., et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 2011, 43:1012-1017.
48. Spinner M.A., Sanchez L.A., Hsu A.P., et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood 2014, 123:809-821.
49. Vinh D.C., Patel S.Y., Uzel G., et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 2010, 115:1519-1529.
50. Hsu A.P., Sampaio E.P., Khan J., et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011, 118:2653-2655.
51. Ostergaard P., Simpson M.A., Connell F.C., et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet 2011, 43:929-931.
52. Pabst T., Eyholzer M., Fos J., Mueller B.U. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer 2009, 100:1343-1346.
53. Renneville A., Roumier C., Biggio V., et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008, 22:915-931.
54. Estey E.H. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 2013, 88:318-327.
55. Taskesen E., Bullinger L., Corbacioglu A., et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011, 117:2469-2475.
56. Udani R, Parlow M, Yin L, Belilissimo D. Novel germline CEBPA sequence variations in familial aml and cytogenetically normal AML. 2012 Annual Meeting of the American Society of Hematology; Atlanta, GA; Dec 8-11, 2012. Abstract no. 2566.
57. Pabst T., Mueller B.U. Complexity of CEBPA dysregulation in human acute myeloid leukemia. Clin Cancer Res 2009, 15:5303-5307.
58. Renneville A., Mialou V., Philippe N., et al. Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. Leukemia 2009, 23:804-806.
59. Paz-Priel I., Friedman A. C/EBPalpha dysregulation in AML and ALL. Crit Rev Oncog 2011, 16:93-102.
60. Preudhomme C., Sagot C., Boissel N., et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002, 100:2717-2723.
61. Fröhling S., Schlenk R.F., Stolze I., et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004, 22:624-633.
62. Bienz M., Ludwig M., Leibundgut E.O., et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005, 11:1416-1424.
63. Marcucci G., Maharry K., Radmacher M.D., et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 2008, 26:5078-5087.
64. Pabst T., Eyholzer M., Haefliger S., et al. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 2008, 26:5088-5093.
65. Debeljak M., Kitanovski L., Pajic T., Jazbec J. Concordant acute myeloblastic leukemia in monozygotic twins with germline and shared somatic mutations in the gene for CCAAT-enhancer-binding protein alpha with 13 years difference at onset. Haematologica 2013, 98:e73-e74.
66. Stelljes M., Corbacioglu A., Schlenk R.F., et al. Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein alpha from hematopoietic cells in a family with AML. Leukemia 2011, 25:1209-1210.
67. Ballew B.J., Savage S.A. Updates on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev Hematol 2013, 6:327-337.
68. Dokal I. Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program 2011, 2011:480-486.
69. Alter B.P., Giri N., Savage S.A., Rosenberg P.S. Cancer in dyskeratosis congenita. Blood 2009, 113:6549-6557.
70. Yamaguchi H., Baerlocher G.M., Lansdorp P.M., et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood 2003, 102:916-918.
71. Armanios M.Y., Chen J.J., Cogan J.D., et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007, 356:1317-1326.
72. Heiss N.S., Knight S.W., Vulliamy T.J., et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 1998, 19:32-38.
73. Walne A.J., Vulliamy T., Kirwan M., Plagnol V., Dokal I. Constitutional mutations in RTEL1 cause severe dyskeratosis congenita. Am J Hum Genet 2013, 92:448-453.
74. Vulliamy T., Marrone A., Goldman F., et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001, 413:432-435.
75. Savage S.A., Giri N., Baerlocher G.M., et al. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet 2008, 82:501-509.
76. Ballew B.J., Yeager M., Jacobs K., et al. Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in dyskeratosis congenita. Hum Genet 2013, 132:473-480.
77. Kirwan M., Vulliamy T., Marrone A., et al. Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Hum Mutat 2009, 30:1567-1573.
78. Marrone A., Walne A., Tamary H., et al. Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome. Blood 2007, 110:4198-4205.
79. Walne A.J., Vulliamy T., Beswick R., Kirwan M., Dokal I. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood 2008, 112:3594-3600.
80. Calado R.T., Regal J.A., Kleiner D.E., et al. A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One 2009, 4:e7926.
81. Alter B.P., Giri N., Savage S.A., et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol 2010, 150:179-188.
82. Young N.S. Bone marrow failure and the new telomere diseases: practice and research. Hematology 2012, 17:S18-S21.
83. Vulliamy T., Marrone A., Szydlo R., et al. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet 2004, 36:447-449.
84. Parry E.M., Alder J.K., Qi X., Chen J.J., Armanios M. Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. Blood 2011, 117:5607-5611.
85. Vulliamy T.J., Walne A., Baskaradas A., et al. Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol Dis 2005, 34:257-263.
86. Armanios M. Telomerase and idiopathic pulmonary fibrosis. Mutat Res 2012, 730:52-58.
87. Alter B.P., Rosenberg P.S., Giri N., et al. Telomere length is associated with disease severity and declines with age in dyskeratosis congenita. Haematologica 2012, 97:353-359.
88. Martens U.M., Brass V., Engelhardt M., et al. Measurement of telomere length in haematopoietic cells using in situ hybridization techniques. Biochem Soc Trans 2000, 28:245-250.
89. de la Fuente J., Dokal I. Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatr Transplant 2007, 11:584-594.
90. Dietz A.C., Orchard P.J., Baker K.S., et al. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant 2011, 46:98-104.
91. Brazzola P., Duval M., Fournet J.C., et al. Fatal diffuse capillaritis after hematopoietic stem-cell transplantation for dyskeratosis congenita despite low-intensity conditioning regimen. Bone Marrow Transplant 2005, 36:1103-1105.
92. Green A.M., Kupfer G.M. Fanconi anemia. Hematol Oncol Clin North Am 2009, 23:193-214.
93. Soulier J. Fanconi anemia. Hematology Am Soc Hematol Educ Program 2011, 492-497.
94. Smith A.R., Wagner J.E. Current clinical management of Fanconi anemia. Expert Rev Hematol 2012, 5:513-522.
95. Kee Y., D'Andrea A.D. Molecular pathogenesis and clinical management of Fanconi anemia. J Clin Invest 2012, 122:3799-3806.
96. Knies K., Schuster B., Ameziane N., et al. Genotyping of Fanconi anemia patients by whole exome sequencing: advantages and challenges. PLoS One 2012, 7:e52648.
97. D'Andrea A.D. Susceptibility pathways in Fanconi[U+05F3]s anemia and breast cancer. N Engl J Med 2010, 362:1909-1919.
98. Butturini A., Gale R.P., Verlander P.C., et al. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood 1994, 84:1650-1655.
99. Kutler D.I., Singh B., Satagopan J., et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003, 101:1249-1256.
100. Gluckman E., Auerbach A.D., Horowitz M.M., et al. Bone marrow transplantation for Fanconi anemia. Blood 1995, 86:2856-2862.
101. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007, 8:735-748.
102. Howlett N.G., Taniguchi T., Olson S., et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002, 297:606-609.
103. Quentin S., Cuccuini W., Ceccaldi R., et al. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood 2011, 117:e161-e170.
104. Faivre L., Guardiola P., Lewis C., et al. Association of complementation group and mutation type with clinical outcome in fanconi anemia. European Fanconi Anemia Research Group. Blood 2000, 96:4064-4070.
105. Kirwan M., Walne A.J., Plagnol V., et al. Exome sequencing identifies autosomal-dominant SRP72 mutations associated with familial aplasia and myelodysplasia. Am J Hum Genet 2012, 90:888-892.
106. Li J., Zhou F., Zhan D., et al. A novel histone H4 arginine 3 methylation-sensitive histone H4 binding activity and transcriptional regulatory function for signal recognition particle subunits SRP68 and SRP72. J Biol Chem 2012, 287:40641-40651.
107. Godley L.A. Profiles in leukemia. N Engl J Med 2012, 366:1152-1153.
108. Points to consider in the clinical application of genomic sequencing. Genet Med 2012, 14:759-761. ACMG Board of Directors.
109. Green R.C., Berg J.S., Grody W.W., et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013, 15:565-574.
110. Biesecker L.G., Burke W., Kohane I., Plon S.E., Zimmern R. Next-generation sequencing in the clinic: are we ready?. Nat Rev Genet 2012, 13:818-824.
111. Shyr D., Liu Q. Next generation sequencing in cancer research and clinical application. Biol Proced Online 2013, 15:4.
112. Greif P.A., Dufour A., Konstandin N.P., et al. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood 2012, 120:395-403.
113. Ho P.A., Alonzo T.A., Gerbing R.B., et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children[U+05F3]s Oncology Group. Blood 2009, 113:6558-6566.
114. Wyatt H.D., Tsang A.R., Lobb D.A., Beattie T.L. Human telomerase reverse transcriptase (hTERT) Q169 is essential for telomerase function in vitro and in vivo. PLoS One 2009, 4:e7176.
115. Vulliamy T.J., Dokal I. Dyskeratosis congenita: the diverse clinical presentation of mutations in the telomerase complex. Biochimie 2008, 90:122-130.
116. Iakhiaeva E., Iakhiaev A., Zwieb C. Identification of amino acid residues in protein SRP72 required for binding to a kinked 5e motif of the human signal recognition particle RNA. BMC Mol Biol 2010, 11:83.